Johnson-Greene Treerita Essalima purchased $26K of OCGN

Johnson-Greene Treerita Essalima (Chief Financial Officer) purchased 21,000 shares of Ocugen, Inc. (OCGN) at $1.23 on 2026-06-15.

Original reporting
SEC EDGAR · Johnson-Greene Treerita Essalima
Published Jun 17, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OCGN
Bullish
medium confidence
Mentioned
$OCGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OCGNBullishLow
01

Why it matters

The newest fact is the CFO’s open-market purchase details (date, shares, price, and post-transaction holdings). This can slightly improve sentiment but does not introduce new operational or financial guidance.

02

Market read

Traders may treat the filing as a small bullish sentiment datapoint, but it is unlikely to be a standalone catalyst.

03

What to watch

The filing provides no context on whether the purchase reflects a broader conviction versus a planned trading pattern; traders should wait for operational catalysts (trial updates, financing, guidance) to confirm any thesis.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-17; transaction dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Ocugen, Inc. (OCGN).

Company-level read

Ticker impact

$OCGNBullishMedium confidence
Context

Ocugen CFO Johnson-Greene Treerita Essalima filed a Form 4 open-market purchase of 21,000 shares at $1.23 on 2026-06-15.

Expected impact

Near-term sentiment lift possible, but limited fundamental impact; any price reaction is likely muted.

Evidence & confidence

The article discloses a new SEC Form 4 buy (primary source) with a specific price and share count, yet it is a single officer’s open-market purchase without additional company catalysts (earnings, trial, guidance, financing).

Market effects

No sector-wide read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or routine compensation-related activity; without a 10b5-1 plan and with a relatively small dollar amount, follow-through may be limited.

Key entities

  • Ocugen, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Johnson-Greene Treerita Essalima

    Ocugen CFO who purchased 21,000 shares open-market at $1.23 on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OCGNHigh

Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises

Ocugen reported Q3 2026 earnings with a loss of 6 cents per share (excluding derivative liability), matching estimates. Revenue rose 11.4% YoY to $1.95M, beating estimates. Shares rose 17.4% post-results. R&D expenses increased 12.1% YoY. The company expects funds to support operations into 2028. Ocugen is advancing its gene therapy pipeline with three BLA submissions targeted by 2028.

$OCGNMedAI 8/10

Ocugen Inc (OCGN) Q3 2026 Earnings Call Highlights: Three Gene Therapy Programs Reach Phase

Ocugen Inc (OCGN) reported Q3 2026 earnings, highlighting progress in three gene therapy programs. OCU-400 Phase 3 trial expects 50% response rate, with top-line data due Q1 2027. OCU-410 trials for geographic atrophy and Stargardt disease are on track, with data readouts expected in 2027. The company has $84.6M cash runway into 2028. Licensing deals for OCU-400 in the Middle East and South Korea were announced, with potential milestone payments and royalties.

$OCGNMed

Ocugen (OCGN) Q3 2026 Earnings Call Transcript

Ocugen reported Q3 2026 progress, with all three late-stage gene therapy programs in phase III. OCU400 for retinitis pigmentosa completed enrollment, with top-line data expected in Q1 2027. The company secured a $4M upfront license deal for the Middle East and North Africa. Financials showed $84.6M in cash and a $0.01 net loss per share, down from $0.07 in 2025. Ocugen aims to file three BLAs by 2028.